Video Series

The use of cognitive behavioral therapy (CBT) in schizophrenia treatment is examined.

Medical experts discuss current obstacles facing ideal respiratory syncytial virus (RSV) treatment strategies in children.

Adam Welch, PharmD, MBA, FAPhA, leads a discussion surrounding payer considerations for RSV vaccinations in children.

A look at the psychological implications of acne in teenagers and adults.

Discussion on the economic burden of over-counter and prescription drug costs related to acne therapy.

Dr Marshall describes the impacts of microsatellite stability and instability on metastatic colorectal cancer.

Dr Carney drives a discussion surrounding optimal treatment strategies for schizophrenia.

Panelists provide insight into the standards of care for treating patients diagnosed with schizophrenia.

A panel of experts discuss future opportunities with interchangeable biosimilars from payer and provider perspectives.

Conversation on the four classic causes of acne as well as pathogenesis.

Introduction of expert panelists and treatment guidelines for patients with acne.

Discussion on shared decision making with patients with later stage refractory metastatic colorectal cancer as well as maximizing a patient's quality of life.

Maia Kayal, MD, MS, and Kimberly C. Chen, DO, MSHLM, discuss challenges for biosimilars with interchangeable designation related to automatic substitution in the pharmacy.

Kimberly C. Chen, DO, MSHLM, discusses the potential benefits of interchangeable biosimilars to patients and payers.

John L. Marshall M.D., shares insights on health-related quality of life (HRQoL) findings from SUNLIGHT study presented at ESMO World Congress on Gastrointestinal Cancer (ESMO GI) 2023.

A panel of medical experts discuss the clinical and financial considerations surrounding the treatment of patients diagnosed with schizophrenia.

Social determinants of health impacting the treatment landscape for schizophrenia are discussed.

A panel of experts reviews the emerging interchangeable biosimilars and best practices on how to educate providers and patients on these treatment options.

Maia Kayal, MD, MS, and Jonathan Kay, MD, define interchangeability and review the details of a switching study.

Carlos Larrauri, APRN, details the signs and symptoms necessary to make a schizophrenia diagnosis.

John J. Miller, MD, and Nev Jones, PhD, open a discussion providing an overview on the current state of patients with schizophrenia.

With their final thoughts, the panelists emphasize patient-centered care is at the forefront of critical MS treatment considerations for providers.

A comprehensive look into MS treatment objectives is provided.

Panelists provide their closing thoughts on optimizing the management of HIV.

The panel of experts discusses emerging and anticipated changes to the HIV treatment landscape.

A discussion surrounding clinical trials in multiple sclerosis is led by Dr Haumschild.

The panel expands on the role of BTK inhibitors in the MS treatment landscape.

The panel discusses unmet needs that remain in the treatment and management of HIV.